{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T16:09:34Z","timestamp":1786118974545,"version":"build-2736575974"},"reference-count":12,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,1]]},"DOI":"10.1097\/mcg.0b013e31814a4e97","type":"journal-article","created":{"date-parts":[[2008,12,17]],"date-time":"2008-12-17T03:15:26Z","timestamp":1229483726000},"page":"91-92","source":"Crossref","is-referenced-by-count":69,"title":["Rifaximin in Treatment of Recurrent Clostridium difficile-associated Diarrhea: An Uncontrolled Pilot Study"],"prefix":"10.1097","volume":"43","author":[{"given":"Kevin W.","family":"Garey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhi-Dong","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelle","family":"Bellard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herbert L.","family":"DuPont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20210305","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1056\/NEJMoa051590","article-title":"An epidemic, toxin gene-variant strain of Clostridium difficile","volume":"353","author":"McDonald","year":"2005","journal-title":"N Eng J Med"},{"key":"R2-16-20210305","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1046\/j.1198-743x.2001.00289.x","article-title":"Epidemiology of Clostridium difficile-associated infections","volume":"7","author":"Barbut","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"R3-16-20210305","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1053\/j.gastro.2006.02.044","article-title":"Recurrent clostridium difficile","volume":"130","author":"Maroo","year":"2006","journal-title":"Gastroenterology"},{"key":"R4-16-20210305","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1586\/14787210.3.2.201","article-title":"Rifaximin: a nonabsorbable rifamycin antibiotic for use in nonsystemic gastrointestinal infections","volume":"3","author":"Gerard","year":"2005","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R5-16-20210305","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1086\/511870","article-title":"Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin","volume":"44","author":"Johnson","year":"2007","journal-title":"Clin Infect Dis"},{"key":"R6-16-20210305","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1128\/JCM.31.4.963-967.1993","article-title":"Comparison of three enzyme immunoassays, a cytotoxicity assay, and toxigenic culture for diagnosis of Clostridium difficile-associated diarrhea","volume":"31","author":"Barbut","year":"1993","journal-title":"J Clin Microbiol"},{"key":"R7-16-20210305","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1128\/JCM.31.7.1870-1875.1993","article-title":"Development of a rapid and efficient restriction endonuclease analysis typing system for Clostridium difficile and correlation with other typing systems","volume":"31","author":"Clabots","year":"1993","journal-title":"J Clin Microbiol"},{"key":"R8-16-20210305","doi-asserted-by":"crossref","first-page":"805","DOI":"10.7326\/0003-4819-142-10-200505170-00005","article-title":"A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea","volume":"142","author":"DuPont","year":"2005","journal-title":"Ann Intern Med"},{"key":"R9-16-20210305","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1128\/AAC.44.8.2205-2206.2000","article-title":"In vitro activity and fecal concentration of rifaximin after oral administration","volume":"44","author":"Jiang","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-16-20210305","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1159\/000007297","article-title":"In vitro activity of rifaximin, metronidazole and vancomycin against Clostridium difficile and the rate of selection of spontaneously resistant mutants against representative anaerobic and aerobic bacteria, including ammonia-producing species","volume":"46","author":"Marchese","year":"2000","journal-title":"Chemotherapy"},{"key":"R11-16-20210305","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S1542-3565(03)00322-7","article-title":"Enteroaggregative Escherichia coli diarrhea in travelers: response to rifaximin therapy","volume":"2","author":"Infante","year":"2004","journal-title":"Clin Gastroenterol Hepatol"},{"key":"R12-16-20210305","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1111\/j.1572-0241.2002.05839.x","article-title":"Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease","volume":"97","author":"McFarland","year":"2002","journal-title":"Am J Gastroenterol"}],"container-title":["Journal of Clinical Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1097\/MCG.0b013e31814a4e97","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T17:27:31Z","timestamp":1786037251000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00004836-200901000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/mcg.0b013e31814a4e97","relation":{},"ISSN":["0192-0790"],"issn-type":[{"value":"0192-0790","type":"print"}],"subject":[],"published":{"date-parts":[[2009,1]]}}}